2012 ACR/ARHP ANNUAL MEETING session...306 – Systemic Lupus erythematosus: Clinical Aspects 10:15 – 11:00 am 307 – osteoarthritis - Clinical Aspects 308 – rheumatoid Arthritis

P r e - m e e t i n g C o u r s e s : N o v e m b e r 9 - 1 0 , 2 0 1 2

o P e n i n g l e C t u r e a n d awa r d s : N o v e m b e r 10, 2012

o P e n i n g e v e n t: N o v e m b e r 1 0 , 2 0 1 2

s C i e n t i f i C s e s s i o n s : N o v e m b e r 1 0 - 1 4 , 2 0 1 2

sessiont r a C K e r

2 0 1 2 A C R / A R H P A N N U A L M E E T I N G

Call for Proposals and Study Group Applications

This is your opportunity to share your ideas and make a contribution to the 2013 Annual meeting. To view instructions and submit a session proposal, visit www.aCrannualmeeting.org.

Coordinate a study group and create a unique networking opportunity for your colleagues. To view the guidelines and submit an application, visit www.aCrannualmeeting.org.

submission deadline: friday, december 14, 2012 at noon.

session t r a C K e r

1

U se the Session Tracker to record your Cme/Hours of Participation as you go, then use my Cme Tracker as a guide to apply for Cme/Hours of Participation at www.aCrannualmeeting.org and obtain a certificate for your records.

Educational TracksLook for these icons to navigate the meeting by track:

BASIC SCIENCE CLINICAL SCIENCE CLINICAL PRACTICE BUSINESS/ ADMINISTRATION

PM PS PAIN MANAGEMENT PM PS PATIENT SAFETY

accreditation statement: The American College of rheumatology is accredited by the Accreditation Council for Continuing medical education (ACCme) to provide continuing medical education for physicians.

designation statement: The ACr designates this live educational activity for a maximum of 49.75 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

international Physicians: International physicians who register as part of a group and require AMA PRA Category 1 Credit(s)™, must provide the following information to your tour leader: full name, mailing address, telephone and fax numbers, and e-mail address. The information will be used to verify your meeting attendance.

The American medical Association has an agreement of mutual recognition of continuing medical education credit with the european Union of medical Specialties. International physicians interested in converting AMA PRA Category 1 Credit ™ to eACCme credit should contact the UemS.

Health Professionals: Participants may claim hours to receive a Certificate of Participation for an activity designated for AMA PRA Category 1 Credit(s)™. For non-Cme sessions, attendees may also request a certificate of participation.

2


IMPORTANT LOCATIONS

aCr office . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102A; telephone: (202) 249-4001

attendee lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ballroom Pre-Function

Business Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L Street South Lobby (under escalator)

Career Connection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall (Hall A), booth 945

Child Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Call for Location; telephone: (202) 249-4008

Cme/internet Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Concourse (near entrance to Hall A)

Coat/Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . registration (Salons G-H-I)

exhibit Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall A

first aid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall (Hall A, bottom of escalator)

graffiti walls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall (Hall A) & Grand Lobby

Hotel reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . registration (Salons G-H-I)

industry-supported symposia information . . . . . . . . . . . . . . . . . . . L Street South Lobby (under escalator)

innovation theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall A, booth 1451

lost and found . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ACr office (102A)

membership Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . registration (Salons G-H-I)

newsroom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203A-b; telephone: (202) 249-4005

nursing mothers’ room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salon D

Poster Hall . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall b

Prayer room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salon e (east building, Street Level)

recharge areas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall (Hall A, main aisles), Attendee Lounge (ballroom Pre-Function) and large meeting rooms

registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Salons G-H-I (Level 1)

resource Center . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L Street bridge (Level 2)

restaurant reservations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Grand Lobby

Rheumatology Research Foundation 5K run/walk registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . registration (Salons G-H-I)

Rheumatology Research Foundation Booth . . . . . . . . . . . . . . . . . . . L Street bridge (Level 2)

Rheumatology Research Foundation donors’ lounge . . . . . . . east overlook (2nd Floor)


3

ribbon distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . registration (Salons G-H-I)

SessionSelect lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . West overlook (2nd Floor)

shuttle Bus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . L Street

speaker lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 141

speaker ready room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156

visitor information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Grand Lobby

wheelchairs (complimentary-limited availability) . . . . . . . . . . . Information Desk (Grand Lobby)

wi-fi way . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . exhibit Hall (Hall A)

Special NeedsIf you require special arrangements, please contact the ACr office (102A); telephone: (202) 249-4001.

Emergency Contact InformationSpace is provided on the back of your badge to list name and telephone numbers of your emergency contacts. Please complete this information before inserting your badge in your badge holder.

Printing of this publication is supported by Amgen, Inc.

4


Meeting At-A-Glance FRIDAY & SATURDAY, NOVEMBER 9-10

friday, November 9, 2012

Time Title Location CME/Hours of Participation

6:30 am – 6:00 pm

aCr/arHP registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . registration Hall (Salons G-H-I)

Pre-meeting Courses7:30 am – 5:30 pm

aCr musculoskeletal ultrasound Course for rheumatologists – Day one . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

207 A

8.5 hrs

9:00 am – 5:00 pm

aCr Certified rheumatology Coder Course: Unlock the mystery: A roadmap for rheumatology Coding – Day one PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

150 b

1:00 – 6:00 pm

aCr/aBim maintenance of Certification learning session – 2012 Update in rheumatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

146 C

1:00 – 5:55 pm

aCr Basic research Conference: mesenchymal Cells in rheumatic Diseases: Tissue erosion/Invasion vs. Fibrosis – Day one of Two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom A

4.5 hrs

1:00 – 6:00 pm

aCr Clinical research Conference: Pain research: New methods and Challenges – Day one . . . . . . . . . . . . . . . . . . . . . . .

ballroom C

4.5 hrs

saturday, November 10, 2012


6:30 am – 6:30 pm


Pre-meeting Courses7:15 am – 4:30 pm

aCr musculoskeletal ultrasound Course for rheumatologists – Day Two of Two . . . . . . . . . . . . . . . . . . . . . . .

207 A

8.0 hrs

8:00 am – 4:00 pm

aCr review Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall D 6.0 hrs

8:00 am – 4:30 pm

aCr Basic research Conference: mesenchymal Cells in rheumatic Diseases: Tissue erosion/Invasion vs. Fibrosis – Day Two of Two . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom A

5.75 hrs

8:00 am – 4:30 pm

arHP Clinical focus Course: Treating the Patient with osteoarthritis: Interventions, Innovations and Clinical Insights: Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

143 A

7.5 hrs


5

SATURDAY & SUNDAY, NOVEMBER 10-11 Meeting At-A-Glance

8:00 am – 4:30 pm

CorC Pre-meeting Course for Practice managers: Helping You manage A Profitable Practice PM PS . . . . . . . . . . . . . . . . . . . . .

152 A

7.5 hrs

8:30 am – 4:15 pm

aCr Clinical research Conference: Pain research: New methods and Challenges – Day Two of Two . . . . . . . . . . . . . . .

ballroom C

6.25 hrs

11:00 am – 5:00 pm

aCr Certified rheumatology Coder Course examination: unlock the mystery: A roadmap for rheumatology Coding – Day Two of Two PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

150 b

4:30 – 6:15 pm

aCr/arHP opening lecture and awards “Straight and Swift to My Wounded I Go:” The reality of Civil War medicine . . . . . . . . . . . . . . . . . . . . . . . . .

Hall D

0.75 hrs

7:00 – 10:00 pm

aCr/arHP opening event . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Newseum

suNday, November 11, 2012


6:30 am – 6:00 pm


6:00 – 7:30 am

Rheumatology Research Foundation 5K run/walk

7:30 – 8:30 am

aCr sessions modifying Causal risk Factors that Influence the Incidence of Falls by older Adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year in Review . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

146 CHall D

1.0 hrs

7:30 – 9:00 am

aCr sessions Genetics as a Tool for elucidating Autoimmune Disease Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Tips for Publishing Your Work in a Peer–reviewed medical Journal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

204 A 207 A

1.5 hrs

7:45 – 9:00 am

arHP sessions ArHP First-time Attendee orientation . . . . . . . . . . . . . . . . . . . . . . . . . ArHP moderators orientation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

201206

6


Meeting At-A-Glance SUNDAY, NOVEMBER 11


7:45 – 9:15 am

aCr meet the Professor sessions behçet’s Disease (001) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Controversies in Sjögren’s Syndrome (002) . . . . . . . . . . . . . . . . . . . .

Infections with biologics (003) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pediatrics: Dermatomyositis (004) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Pediatrics: Difficult to Treat Juvenile Idiopathic Arthiritis (005) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

rheumatoid Arthritis: biological Agents (006). . . . . . . . . . . . . . . . .

Spondylarthropathy: An Update (007) . . . . . . . . . . . . . . . . . . . . . . . . .

Systemic Arthritis and Still’s Disease (008) . . . . . . . . . . . . . . . . . . . .

Lupus erythematosus: Central Nervous System (009) . . . . . . . . .

vasculitis mimics (010) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

148153154 A154 b 155158 A158 b159 A159 b160

1.5 hrs

7:45 – 9:45 am

aCr workshops basic Statistical Concepts for the medical researcher (201) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Clinical Anatomy and Physical exam: essential Tools in Lower extremity regional Pain Syndromes (202) . . . . . . . . . . . . . . . . . . . . .

Dermatopathology of rheumatic Diseases (203) . . . . . . . . . . . . . .

musculoskeletal exam Skills I: General musculoskeletal examination for Arthritis (204) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

149 A 144 C144 A 144 b

2.0 hrs

9:00 – 10:00 am

aCr sessions Advances in the biology of Aging . . . . . . . . . . . . . . . . . . . . . . . . . .

CorC ForUm: Achieving economic Goals in an era of Healthcare reform . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

New Therapies for modulating Signaling in rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

The Plasticity of T regulatory Cells and their role in Autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Update on Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

150 b 147 A Hall e 152 AHall D

1.0 hr

9:00 – 10:30 am

aCr sessions extra-articular Involvement in rheumatoid Arthritis . . . . . .

medical education: The Year in review . . . . . . . . . . . . . . . . . . . .

202 b145 A

1.5 hrs

session t r a C K e rsession t r a C K e r

7

SUNDAY, NOVEMBER 11 Meeting At-A-Glance


9:00 am – 6:00 pm

aCr Poster session a and Poster tours . . . . . . . . . . . . . . . . . . . . . . .

Abstracts (#1-724)Poster Presentations9:00 – 11:00 amPoster tours9:00 – 9:45 am301 – Fellows only: How to Navigate the Poster Hall 302 – osteoarthritis: Clinical Aspects 303 – Pediatric rheumatology: Clinical Aspects 304 – rheumatoid Arthritis: Clinical Aspects 305 – rheumatoid Arthritis: Treatment: Small molecules,

biologics and Gene Therapy 306 – Systemic Lupus erythematosus: Clinical Aspects 10:15 – 11:00 am307 – osteoarthritis - Clinical Aspects 308 – rheumatoid Arthritis Treatment - Small molecules,

biologics and Gene Therapy 309 – rheumatoid Arthritis: Clinical Aspects 310 – Spondylarthropathies and Psoriatic Arthritis: Clinical

Aspects and Treatment 311 – Systemic Lupus erythematosus: Clinical Aspects

Poster Hall (Hall b)

2.0 hrs

9:30 – 10:30 am

arHP session Keynote Address: It’s Not Child’s Play: Growing Up With and mastering Juvenile Idiopathic Arthritis from the Child’s Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

146 C

1.0 hr

10:00 – 11:00 am

Rheumatology Research Foundation special session oscar S. Gluck, mD, memorial Lectureship: bone Wasn’t built in a Day: New Insights into Destruction and repair in rheumatic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom b

1.0 hr

10:00 am – 5:00 pm

exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

exhibit Hall morning Snack break (10:00 – 11:00 am)exhibit Hall Afternoon Snack break (2:00 – 3:00 pm)Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (10:30 – 11:15 am and 2:30 – 3:15 pm) See page 29 for the list of presentations.

exhibit Hall (Hall A)

exhibit Hall (Hall A) – booth #1451

10:30 am – 12:30 pm

aCr workshops Adult musculoskeletal Upper examinations (205) . . . . . . . . . . . . .

musculoskeletal Ultrasound (206) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

renal Histopathology in Systemic Lupus erythematosus and vasculitis (207) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

144 C144 b 149 A

2.0 hrs

8



8


11:00 am – 12:30 pm

aCr Plenary session i – discovery 2012 Abstracts (#725-729) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Hall D

1.5 hrs

11:00 am – noon

arHP sessionsHands: Non-Surgical management and bracing – What You Don’t Know Can Hurt You . . . . . . . . . . . . . . . . . . . . . . . . . . .New medication Developments in rheumatology . . . . . . .rheumatic Disease Update: vasculitis . . . . . . . . . . . . . . . . .The 5A Approach to Physical Activity Counseling for Arthritis Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

206143 A204 A 201

1.0 hrs

12:30 – 1:45 pm

aCr sessionACr Knowledge bowl – Preliminary round . . . . . . . . . . . . . 202 b

1.25 hrs

12:30 – 2:15 pm

arHP networking eventArHP Networking Forum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Renaissance

Washington – Renaissance ballroom, east & West

12:45 – 2:15 pm

aCr meet the Professor sessions Adult Inflammatory myopathy (011) . . . . . . . . . . . . . . . . . . . . .Cutaneous vasculitis (012) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Inflammatory eye Disease/Uveitis (013) . . . . . . . . . . . . . . . . . .myopathy: Issues in Diagnosis and Treatment (014) . . . . . . . .osteoporosis: Novel Treatments (015) . . . . . . . . . . . . . . . . . . .Pediatrics: Periodic Fevers in Children (016) . . . . . . . . . . . . . . .Polymyalgia rheumatica (017) . . . . . . . . . . . . . . . . . . . . . . . . . .Pregnancy in rheumatic Diseases (018) . . . . . . . . . . . . . . . . . .Systemic Lupus erythematosus: Novel Treatments (019) . . . . .vitamin D and bone Health (020) . . . . . . . . . . . . . . . . . . . . . . . .

148153154 A154 b155158 A158 b159 A159 b160

1.5 hrs

1:00 – 2:00 pm

aCr sessionsendoplasmic reticulum Stress Unfolded Protein response in Immunity and Inflammation . . . . . . . . . . . . . . . . . . . . . . .mechanisms of Pain in rheumatic Diseases . . . . . . . . . . . .Preoperative Assessment and Perioperative management of the Patient with rheumatic Disease: What every rheumatologist Should Know (Clinical review) . . . . . . . . . .

204 A146 C Hall e

1.0 hrs


9

SUNDAY, NOVEMBER 11 Meeting At-A-Glance

9

1:15 – 3:15 pm

aCr workshopsDesigning a Website for Your Practice (208) . . . . . . . . . . . . . . .muscle Involvement in rheumatic Diseases (209) . . . . . . . . . .Physical examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (210) . . . . . .renal Histopathology in Systemic Lupus erythematosus and vasculitis (211) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

149 b144 A 144 C 149 A

2.0 hrs

2:30 – 4:00 pm

aCr sessionsComplementary and Alternative medicine: evidence based options for Arthritis Patients PM PS . . . . . . . . . . . . . . . . . . . . . . .Prospects for Prevention and Cure of rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .The Great Debate: In 2012 what are the roles of Cyclophosphamide versus rituximab in ANCA-Associated vasculitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Update on Treatment of Systemic Lupus erythematosus . .

ballroom A Salon b Hall DHall e

1.5 hrs

2:30 – 4:00 pm

aCr Concurrent abstract sessions(#730-735) biology and Pathology of bone and Joint: osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#736-740) Cytokines, mediators, and Gene regulation I Includes 2011 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#741-746) epidemiology and Health Services research I: epidemiology and outcomes in rheumatic Disease . . . . . . . . .(#747-752) miscellaneous rheumatic and Inflammatory Diseases: Periodic Fever Syndromes . . . . . . . . . . . . . . . . . . . . .(#753-758) muscle biology, myositis and myopathies: Classification, Treatment and outcome in Idiopathic Inflammatory myopathies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#759-764) Pediatric rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I . . . . . . . . . . . . . . . . . . .(#765-770) rheumatoid Arthritis – Clinical Aspects I: risk Factors and Prediction of rheumatoid Arthritis . . . . . . . . . . . .(#771-776) rheumatoid Arthritis Treatment – Small molecules, biologics and Gene Therapy: Comparative efficacy and Novel Treatment Strategies in rheumatoid Arthritis . . . . .(#777-782) Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment: Spondyloarthritis I . . . . . . . . .(#783-788) Systemic Sclerosis, Fibrosing Syndromes and raynaud’s – Pathogenesis, Animal models and Genetics . . . . .

150 b 147 A 202 b 145 A 152 A 207 A ballroom CRenaissance Washington – Grand ballroom North

ballroom b 146 C

1.5 hrs


10




2:30 – 4:00 pm

arHP sessionsNon-pharmacological management of Fibomyalgia: Your Toolbox PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Practice managers: Improving Access and Website marketing (Practice management Series) . . . . . . . . . . . . . . . . . . . . . . .rheumatic Disease Update: Inflammatory eye Disease . . .

143 A 204 A206

1.5 hrs

2:30 – 4:00 pm

arHP Concurrent abstract sessions(#789-794) Foot and Gait Disorders . . . . . . . . . . . . . . . . . . . . . . (#795-800) osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

140 A201

1.5 hrs

4:00 – 6:00 pm

aCr workshops Dermatopathology of rheumatic Diseases (212) . . . . . . . . . . .musculoskeletal exam Skills II: regional musculoskeletal examination of the Neck and Low back (213) . . . . . . . . . . . . . .osteoporosis: Interpreting Dual energy X-ray Absorptiometry and Clinical risk Factors: The New Fracture risk Assessment Algorithm (214) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Synovial Fluid Analysis and Crystal Identification (215) . . . . . .

144 A 144 b 144 C149 A

2.0 hrs

4:30 – 6:00 pm

aCr sessionsClassification and Treatment of Sjögren’s Syndrome . . . . .metabolic Abnormalities in Autoimmunity . . . . . . . . . . . . .Puberty, Adolescence and rheumatologic Disease . . . . . . .Thieves’ market: Show me Your best Cases . . . . . . . . . . . . .Update on Psoriatic Arthritis and the Spondylarthropathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom C143 A207 AHall D Hall e

1.5 hrs

4:30 – 6:00 pm

aCr Concurrent abstract sessions(#801-806) Fibromyalgia and Soft Tissue Disorders I . . . . . . . .(#807-812) Imaging of rheumatic Diseases I: Ultrasound and X-ray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#813-818) metabolic and Crystal Arthropathies: Clinical . . . .(#819-824) osteoporosis and metabolic bone Disease . . . . . .(#825-830) rheumatoid Arthritis – Clinical Aspects II: Long-term outcome of rheumatoid Arthritis, observational Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#831-836) rheumatoid Arthritis Treatment – Small molecules, biologics and Gene Therapy: efficacy and Safety of Novel entities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#837-842) Systemic Lupus erythematosus – Clinical Aspects and Treatment I: renal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#843-848) Systemic Lupus erythematosus – Human etiology and Pathogenesis I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#849-854) Systemic Sclerosis, Fibrosing Syndromes, and raynaud’s – Clinical Aspects and Therapeutics I . . . . . . . . . . . .(#855-860) vasculitis: Pathogenesis . . . . . . . . . . . . . . . . . . . . . .

202 b Salon b 152 A150 b Renaissance Washington – Grand ballroom North

ballroom A ballroom b 145 A 146 C147 A

1.5 hrs


11

SUNDAY & MONDAY, NOVEMBER 11-12 Meeting At-A-Glance

4:30 – 6:00 pm

aCr meet the Professor sessions Ankylosing Spondylitis: 2012 Update (021) . . . . . . . . . . . . . . . .Antiphospholipid Syndrome (022) . . . . . . . . . . . . . . . . . . . . . . .Crystal: Diagnosis and management of Gout (023) . . . . . . . . .Immunodeficiency Syndromes (024) . . . . . . . . . . . . . . . . . . . . .Pain: evaluation and Treatment of back Pain (025) PM PS . . . . . .Psoriatic Arthritis (026) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Pulmonary Hypertension in the rheumatic Diseases (027) . . .rheumatoid Arthritis: Challenging Cases (028) . . . . . . . . . . . . .rheumatoid Arthritis: outcome measures in Clinical Practice (029) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Temporal Arteritis (030) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

148153154 A154 A155158 A158 b159 A 159 b160

1.5 hrs

4:30 – 6:00 pm

arHP sessionsIncome Inequities Are Perilous to People with Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Practice management: Patients As Partners in Design and Delivery (Practice management Series) . . . . . . . . . . . . . . . .

201 204 A

1.5 hrs

4:30 – 6:00 pm

arHP Concurrent abstract sessions(#861-865)Pediatrics: Disease Flares . . . . . . . . . . . . . . . . . . . . .(#866-871) Psychological Aspects of rheumatologic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

206 140 A

1.5 hrs

6:30 – 9:30 pm

industry-supported symposiaSee program book for the list of symposia.

moNday, November 12, 2012


6:30 am – 6:00 pm


7:30 – 8:30 am

aCr sessionsClinicopathologic Conference: A Patient with Hepatitis C and Inflammatory Polyarticular Arthritis . . . . . . . . . . . . . . .Cross-Sectional Imaging Techniques for rheumatology . . .

Immune Tolerance: From Theory and Clinical Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2012 Hench Lecture: Synovial Immunobiology and response to Therapy in Rheumatoid . . . . . . . . . . . . . . . . . . . . . . . . . . .

Hall DRenaissance Washington – Grand ballroom Northballroom A Salon b

1.0 hrs

12


Meeting At-A-Glance MONDAY, NOVEMBER 12


7:30 – 8:30 am

arHP sessionsDisparities in the Use of Joint Arthroplasty: A Pervasive matter Leading to Inequitable Care (Arthroplasty/Joint replacement Series) PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . .Incorporating Physician Assistants and Nurse Practitioners into rheumatology Practice PM PS . . . . . . . . . . . . . . . . . . . . . .Infusion room Information for medical Professionals (Infusion Series) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .New and better Habits! Facilitating Patient Self-management with Proven behavior Change Strategies PM PS . . . . . . . . . . . .

201 206 204 A 143 A

1.0 hrs

7:30 – 9:00 am

aCr sessionILAr – The Current rheumatology Workforce Across the Globe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

202 b

1.5 hrs

7:45 – 9:15 am

aCr meet the Professors sessions Crystal: Diagnosis and management of Gout (031) . . . . . . . . .osteoarthritis: Update 2012 (032) . . . . . . . . . . . . . . . . . . . . . . .Pediatric rheumatology for Adult rheumatologists (033) . . . .Pediatrics: Spondylarthritis in Children (034) . . . . . . . . . . . . . .Psoriatic Arthritis (035) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .rheumatoid Arthritis: Difficult Cases (036) . . . . . . . . . . . . . . . .rheumatoid Arthritis: Difficult Cases (037) . . . . . . . . . . . . . . . .Scleroderma: Systemic Sclerosis (038) . . . . . . . . . . . . . . . . . . . .Scleroderma: Systemic Sclerosis (039) . . . . . . . . . . . . . . . . . . . .vasculitis: Update (040) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

148153154 A154 b155158 A158 b159 A159 b160

1.5 hrs

7:45 – 9:45 am

aCr/arHP workshops Joint Injections (Knee and Ankle Prosthetics) (216) . . . . . . . . .musculoskeletal Ultrasound (217) . . . . . . . . . . . . . . . . . . . . . . .Peripheral magnetic resonance Imaging in rheumatology Practice (218) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .X-ray Challenges in rheumatic Diseases (219) . . . . . . . . . . . . .

144 C144 b 144 A149 A

2.0 hrs

9:00 – 10:00 am

aCr sessionsepigenetic Factors in Autoimmune Disease . . . . . . . . . . . . .New Anticoagulants: What a Hematologist Thinks a rheumatologist Needs to Know! . . . . . . . . . . . . . . . . . . . . .

152 A Hall D

1.0 hrs

Rheumatology Research Foundation special sessionmemorial Lectureship: Pathogenesis of rheumatoid Arthritis: The voyage from Pre-rheumatoid Arthritis to Joint Destruction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Hall e


13

MONDAY, NOVEMBER 12 Meeting At-A-Glance

13


9:00 – 10:00 am

arHP sessionsClinical Trials: Participation and recruitment . . . . . . . . . . .Infusion reactions: management and Prevention (Infusion Series) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Issues in the management of rheumatic Disease in Patients Undergoing Joint replacement (Arthroplasty/Joint replacement Series) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .rheumatic Disease Update: Gout . . . . . . . . . . . . . . . . . . . .

143 A 204 A 201206

1.0 hrs

9:00 – 10:30 am

aCr sessionsCreating an efficient rheum Practice . . . . . . . . . . . . . . . . . .Legislative Update from Capitol Hill . . . . . . . . . . . . . . . . . . .Update on Safety Issues in the Treatment of rheumatic Diseases – From the Food and Drug Administration and Beyond PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

150 b147 A 207 A

1.5 hrs

9:00 – 10:30 am

Rheumatology Research Foundation special sessionClinician Scholar educator Presentations . . . . . . . . . . . . . . . 145 A

1.5 hrs

9:00 am – 6:00 pm

aCr/arHP Poster session B, thieves’ market and Poster . . . toursAbstracts (#872-1592)

Poster Presentations9:00 – 11:00 amPoster tours9:00 – 9:45 am312 – ArHP Patient Care and Clinically-Focused research 313 – orthopedics, Low back Pain and rehabilitation 314 – rheumatoid Arthritis: Clinical Aspects315 – Spondylarthropathies and Psoriatic Arthritis: Clinical

Aspects and Treatment 316 – Systemic Sclerosis, Fibrosing Syndromes, and

raynaud’s: Clinical Aspects and Therapeutics317 – vasculitis10:15 – 11:00 am318 – Fibromyalgia and Soft Tissue Disorder 319 – osteoarthritis - Clinical Aspects 320 – rheumatoid Arthritis Treatment - Small molecules,

biologics and Gene Therapy 321 – rheumatoid Arthritis: Clinical Aspects 322 – Systemic Lupus erythematosus: Clinical Aspects323 – Rheumatology Research Foundation - Health Services/

Outcomes Research


2.0 hrs

14




10:00 am – 5:00 pm

exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

exhibit Hall morning Snack break (10:00 – 11:00 am)exhibit Hall Afternoon Snack break (2:00 – 3:00 pm)Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (10:30 – 11:15 pm, 12:30 – 1:15 pm and 2:30 – 3:15 pm) See page 29 for the list of presentations.



10:30 – 11:30 am

arHP sessionDistinguished Lecturer: Unraveling the “Go-Gene” . . . . . . . 206

1.0 hrs

10:30 am – 12:30 pm

aCr workshopsmusculoskeletal exam Skills III: regional musculoskeletal examination of the Shoulder and Knee (220) . . . . . . . . . . . . . .osteoporosis: Interpreting Dual energy X-ray Absorptiometry and Clinical risk Factors: The New Fracture risk Assessment Algorithm (221) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

144 b 144 A

2.0 hrs

11:00 am – 12:30 pm

aCr Plenary session ii: discovery 2012(Abstracts #1593-1598) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall e

1.5 hrs

11:00 am – 12:30 pm

aCr sessionsACr Knowledge bowl – Final round . . . . . . . . . . . . . . . . . .Career opportunities in rheumatology: making a Choice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .New Developments in Systemic Juvenile Idiopathic Arthritis management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .The Connected rheumatology Practice: electronic Health record and Social media Implementation and Customization PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Hall D 147 A ballroom C 152 A

1.5 hrs

noon – 2:00 pm

arHP networking eventArHP Networking at Noon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Renaissance

Washington – Renaissance ballroom, east & West


15



12:45 – 2:15 pm

aCr meet the Professors sessions Ankylosing Spondylitis: 2012 Update (041) . . . . . . . . . . . . . . . .basic Immunology for Clinical rheumatologists (042) . . . . . . .Challenging Cases in osteoporosis management (043) . . . . . .Dermatological manifestations of rheumatic Diseases (044) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hereditary Angioderma (045) . . . . . . . . . . . . . . . . . . . . . . . . . . .Pulmonary manifestations of rheumatic Disease (046) . . . . . .raynaud’s and Digital Ischemia (047) . . . . . . . . . . . . . . . . . . . . .Scleroderma mimics (048) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .vaccinations for Patients on biologic Therapies (049) . . . . . . .vasculitis: Update (050) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

148153154 A 154 b155158 A158 b159 A159 b160

1.5 hrs

1:00 – 2:00 pm

aCr sessionsComplex regional Pain Syndrome/reflex Sympathetic Dystrophy: recent Advances, Current Thoughts PM PS . . . . .Innovation in musculoskeletal Curriculum Development: Lessons from New medical Schools . . . . . . . . . . . . . . . . . . .Pediatric rheumatology Town Hall meeting . . . . . . . . . . . .Scleroderma bowel Disease: From Top to bottom (Clinical review) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom A 152 A201 Hall e

1.0 hrs

1:15 – 3:15 pm

aCr/arHP workshops Histopathology of vasculitis (222) . . . . . . . . . . . . . . . . . . . . . . .Joint Injections (Shoulder and Wrist Prosthetics) (223) . . . . . .mrI in the Diagnosis and management of Spondylarthritis: A Clinician’s Guide (224) . . . . . . . . . . . . . . . . .

149 b144 C 144 b

2.0 hrs

2:30 – 4:00 pm

aCr sessionsCurbside Consults – Ask the Professors . . . . . . . . . . . . . . . . macrophage and Dendritic cell Heterogeneity in Tissue Inflammation and Fibrosis . . . . . . . . . . . . . . . . . . . . . . . . . . .mechanotransduction in bone and Cartilage . . . . . . . . . . .Neuropsychiatric Lupus in Children and Adolescents . . . . .osteoporosis: From bisphosphonates and beyond . . . . . . .

Hall D Renaissance Washington – Grand ballroom North

152 Aballroom Cballroom A

1.5 hrs

16




2:30 – 4:00 pm

aCr Concurrent abstract sessions(#1599-1603) Cell-cell Adhesion, Cell Trafficking and Angiogenesis Includes 2011 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#1604-1609) epidemiology and Health Services research II: epidemiologic risk Factors in the Development of rheumatic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#1610-1615) Genetics and Genomics of rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#1616-1621) Imaging of rheumatic Diseases II: magnetic resonance Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#1622-1627) Infection-related rheumatic Disease . . . . . . . . .(#1628-1633) metabolic and Crystal Arthropathies: basic Science . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#1634-1639) rheumatoid Arthritis – Animal models . . . . . . .(#1640-1645) rheumatoid Arthritis Treatment – Small molecules, biologics and Gene Therapy: Safety I . . . . . . . . . . .(#1646-1651) Systemic Lupus erythematosus – Clinical Aspects and Treatment II: Clinical Aspects/Pregnancy . . . . . . .(#1652-1657) vasculitis: Clinical Trials . . . . . . . . . . . . . . . . . . . .

140 A Salon b 145 A 202 b150 b 147 A207 A Hall e ballroom b146 C

1.5 hrs

2:30 – 4:00 pm

arHP sessionsDemystifying the Study Section: How Grants Are reviewed and Scored . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Depression in rheumatic Diseases . . . . . . . . . . . . . . . . . . .minimizing Falls in Geriatric rheumatic Populations . . . . .Total Knee Arthroplasty rehabilitation: optimizing Functional outcomes through examination of Patient Factors, Practice variation and best Practice recommendations (Arthroplasty/Joint replacement Series) . . . . . . . . . . . . . . . . . . . . . . . . . .

143 A204 A206 201

1.5 hrs

4:00 – 6:00 pm

aCr workshops Getting electronic Health record right (225) . . . . . . . . . . .musculoskeletal Ultrasonography: basic (226) . . . . . . . . . .Patient Questionnaires: multi-Dimensional Health Assessment Questionnaire/routine Assessment of Patient Index Data 3 and beyond toward a Standard, Scientific, Quantitative Patient History (227) . . . . . . . . . . . . . . . . . . . .Systemic Sclerosis: How to Perform Skin Scores (228) . . . .

149 b144 b 144 A144 C

2.0 hrs


17



4:30 – 6:00 pm

aCr sessions Aging and the rheumatic Diseases . . . . . . . . . . . . . . . . . . . .Dermatology Topics for rheumatologists: What You Need to Know . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .energetics, metabolism and osteoarthritis . . . . . . . . . . . . .Gout and Hyperuricemia: Diseases beyond the Joint . . . . .Preclinical Autoimmunity – Potential for Prevention . . . . .

150 b Hall D152 ASalon bballroom C

1.5 hrs

4:30 – 6:00 pm

aCr Concurrent abstract sessions (#1658-1663) Cytokines, mediators, and Gene regulation II . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#1664-1669) epidemiology and Health Services research III: rheumatic Diseases and Cardiovascular Disease and risk Assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#1670-1675) muscle biology, myositis and myopathies: Pathogenesis in Idiopathic Inflammatory myopathies . . . . . . .(#1676-1681) Pediatric rheumatology: Clinical and Therapeutic Disease II: Juvenile Idiopathic Arthritis II . . . . . . .(#1682-1687) rheumatoid Arthritis – Clinical Aspects III: rheumatoid Arthritis and Cardiovascular Disease . . . . . . . . . .(#1688-1693) rheumatoid Arthritis – Human etiology and Pathogenesis I: early Pathogenesis of rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#1694-1699) rheumatoid Arthritis Treatment – Small molecules, biologics and Gene Therapy: Safety II . . . . . . . . . . .(#1700-1705) Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment: Spondyloarthritis II . . . . . . . .(#1706-1711) Systemic Lupus erythematosus – Clinical Aspects and Treatment III: Cardiovascular . . . . . . . . . . . . . . . . . (#1712-1717) Systemic Sclerosis, Fibrosing Syndromes, and raynaud’s – Clinical Aspects and Therapeutics II . . . . . . . . . . .

140 A ballroom b 202 b 207 A ballroom A 146 C Hall e 145 A

Renaissance Washington – Grand ballroom North

147 A

1.5 hrs

18




4:30 – 6:00 pm

aCr meet the Professor sessions Adult Inflammatory myopathy (051) . . . . . . . . . . . . . . . . . . . . .Antiphospholipid Syndrome (052) . . . . . . . . . . . . . . . . . . . . . . .Controversies in Sjögren’s Syndrome (053) . . . . . . . . . . . . . . . .Dermatological manifestations of rheumatic Diseases (054) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Fibromyalgia and Dysautonomia (055) . . . . . . . . . . . . . . . . . . .Pain: evaluation and Treatment of back Pain (056) PM PS . . . . . .Pediatric Systemic Lupus (057) . . . . . . . . . . . . . . . . . . . . . . . . . .Psoriatic Arthritis (058) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .rheumatoid Arthritis: biological Agents (059) . . . . . . . . . . . . .Systemic Lupus erythematosus: Difficult to Treat Systemic Lupus erythematosus (060) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

148153154 A 154 b155 158 A158 b159 A159 b 160

1.5 hrs

4:30 – 6:00 pm

arHP sessions early rehabiliation for Hip and Foot osteoarthritis: opportunities and Challenges . . . . . . . . . . . . . . . . . . . . . . .Novel Approaches to Pain management in Juvenile Idiopathic Arthritis PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Promoting Participation: Where Is the Field and Where Do We Go Next? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

201 204 A 143 A

1.5 hrs

4:30 – 6:00 pm

arHP Concurrent abstract session (#1718-1723) Care of Patients with rheumatoid Arthritis . . . . 206

1.5 hrs


19

MONDAY & TUESDAY, NOVEMBER 12-13 Meeting At-A-Glance

6:45 – 7:45 pm

aCr study groups ACr-eULAr Study Group – Signal Transduction in the rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Antiphospholipid Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . .Autoantibodies in Diagnosis and Follow-up of rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Childhood vasculitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Clinical research methodology . . . . . . . . . . . . . . . . . . . . . . . . .Degos Disease and other Atypical vasculopathies . . . . . . . . . .Geriatric rheumatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Global Health Initiatives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Gout Classification Criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hypermobility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Interstitial Lung Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(JAW) Juvenile Arthritis Workgroup . . . . . . . . . . . . . . . . . . . . . .macrophage Activation Syndrome . . . . . . . . . . . . . . . . . . . . . . .musculoskeletal Ultrasound . . . . . . . . . . . . . . . . . . . . . . . . . . . .myositis: New Developments on myositis Therapies . . . . . . . .Neuro endocrine Immunology . . . . . . . . . . . . . . . . . . . . . . . . . .osteoarthritis – Synovial Inflammation . . . . . . . . . . . . . . . . . . .Pediatric rheumatologists Interested in medical education . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Pediatric rheumatology Imaging . . . . . . . . . . . . . . . . . . . . . . . .Skin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

145 A147 A 150 b152 A158 A159 b158 b201206143 A204 A154 b146 C207 A202 b140 A154 A 155159 A148

tuesday, November 13, 2012


6:30 am – 6:00 pm


7:30 – 8:30 am

aCr sessionsChronic recurrent multifocal osteomyelitis . . . . . . . . . . . .molecular and Cellular basis of Tissue Homing . . . . . . . . . .Update on Immune mediated Glomerular Disease . . . . . .

ballroom b152 AHall D

1.0 hrs

7:30 – 8:30 am

Rheumatology Research Foundation special sessionPaul Klemperer, mD memorial Lectureship: Serum Autoantibodies in Systemic Sclerosis: Usefulness in Diagnosis, Clinical Subsetting and Predicting outcomes . . . . . . . . . . . .

ballroom C

1.0 hrs

20


Meeting At-A-Glance TUESDAY, NOVEMBER 13


7:30 – 8:30 am

arHP sessionsClinical and epidemiologic Study Designs in rheumatic Disease research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Don’t Let the Pink Sheets make You blue . . . . . . . . . . . . . .Fungal Infections and Tuberculosis in Patients with rheumatologic Disease (Infection Series) . . . . . . . . . . . . . .

201143 A 145 A

1.0 hrs

7:45 – 9:15 am

aCr meet the Professors sessions Ankylosing Spondylitis: Disease modification (061) . . . . . . . . .Crystal: Diagnosis and management of Gout (062) . . . . . . . . .Infections with biologics (063) . . . . . . . . . . . . . . . . . . . . . . . . . .osteoarthritis: Update 2012 (064) . . . . . . . . . . . . . . . . . . . . . . .Pain: Dealing with Patients with refractory Pain in musculoskeletal and Autoimmune Disorders (065) PM PS . . . . . .Pediatrics: Juvenile Idiopathic Arthritis for Adult rheumatologists (066) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Pregnancy in rheumatic Diseases (067) . . . . . . . . . . . . . . . . . .reactive Arthritis: An Update (068) . . . . . . . . . . . . . . . . . . . . . .Scleroderma: Systemic Sclerosis (069) . . . . . . . . . . . . . . . . . . . .vasculitis: Update (070) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

148153154 A154 b 155 158 A158 b159 A159 b160

1.5 hrs

7:45 – 9:45 am

aCr/arHP workshops Adult musculoskeletal Lower examinations (229) . . . . . . . . . .Knee braces and Foot orthosis for Knee osteoarthritis (230) . .Peripheral magnetic resonance Imaging in rheumatology Practice (231) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Synovial Fluid Analysis and Crystal Identification (232) . . . . . .

144 C144 A 144 b149 A

2.0 hrs

9:00 – 10:00 am

aCr sessionsAdvances in Targeting of b cell Survival Factors . . . . . . . . .Systems Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom A147 A

1.0 hrs

9:00 – 10:00 am

arHP sessionsHepatitis in Patients with rheumatologic Disease (Infection Series) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .rheumatic Disease Update: The Approach to Low back Pain PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Threats to validity: Confounding in rheumatic Disease research (research Series) . . . . . . . . . . . . . . . . . . . . . . . . . .

145 A 143 A 201

1.0 hrs

9:00 – 10:30 pm

aCr sessionsContract Negotiations for Physicians . . . . . . . . . . . . . . . . . .Paradigm Shifts in rheumatoid Arthritis . . . . . . . . . . . . . . .The Guide to meaningful Use and beyond . . . . . . . . . . . . .

150 bHall DRenaissance Washington – Grand ballroom North

1.5 hrs


21

TUESDAY, NOVEMBER 13 Meeting At-A-Glance


9:00 – 10:30 am

Rheumatology Research Foundation special sessionDisease Targeted research . . . . . . . . . . . . . . . . . . . . . . . . . . 207 A

1.5 hrs

9:00 – 10:30 am

arHP Concurrent abstract sessions(#2431-2436) Physical/occupational Therapy and exercise in Patients with rhematologic Disease . . . . . . . . . . . . . . . . . . . . .(#2437-2442) Programs and Literacy in Patients with rheumatologic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

206 204 A

1.0 hrs

9:00 am – 6:00 pm

aCr/arHP Poster session C, thieves’ market Posters and Poster tours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Abstracts (#1724-2430)Poster Presentations9:00 – 11:00 amPoster tours9:00 – 9:45 am324 – ArHP epidemiology and Public Health 325 – miscellaneous rheumatic and Inflammatory Diseases 326 – rheumatoid Arthritis: Clinical Aspects 327 – Systemic Lupus erythematosus: Human etiology and

Pathogenesis 328 – vasculitis10:15 – 11:00 am329 – Antiphospholipid Syndrome 330 – Fibromyalgia and Soft Tissue Disorder 331 – metabolic and Crystal Arthropathies 332 – osteoporosis and metabolic bone Disease: Clinical

Aspects and Pathogenesis 333 – Sjögren’s Syndrome 334 – Rheumatology Research Foundation - Pathogenic

mechanisms in rheumatic Diseases


2.0 hrs

10:00 am – 5:00 pm

exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

exhibit Hall morning Snack break (10:00 – 11:00 am)exhibit Hall Afternoon Snack break (2:00 – 3:00 pm)Innovation Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (10:30 – 11:15 pm, 12:30 – 1:15 pm and 2:30 – 3:15 pm) See page 29 for the list of presentations.



10:30 – 11:30 am

aCr sessionGouty Inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

146 C

1.0 hrs

10:30 – 11:30 am

arHP sessionsImmunizations in Patients with rheumatologic Disease (Infection Series) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Selection bias in rheumatic Disease research – risk Factor Paradox and other Issues . . . . . . . . . . . . . . . . . . . . . . . . . . .

145 A 201

1.0 hrs

22




10:30 am – noon

aCr/arHP Combined abstract session(#2443-2448) ACr/ArHP Combined rehabilitation Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

140 A

1.5 hrs

10:30 am – 12:30 pm

aCr workshops Histopathology of vasculitis (233) . . . . . . . . . . . . . . . . . . . . . . .Joint Injection Techniques (234) . . . . . . . . . . . . . . . . . . . . . . . . .

149 b144 C

2.0 hrs

11:00 – noon

arHP sessionsA Practical Understanding of Function in rheumatoid Arthritis: A multidisciplinary Perspective . . . . . . . . . . . . . .Strategies to enhance office efficiencies and Access to Care in rheumatology Practice PM PS . . . . . . . . . . . . . . . . . . . . . . . .

204 A 143 A

1.0 hrs

11:00 am – 12:30 pm

aCr Plenary session iii – discovery 2012 Abstracts (#2449-2454) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Hall e

1.5 hrs

11:00 – 12:30 pm

aCr sessions microbiome Influence on Autoimmunity . . . . . . . . . . . . . . .Polymyalgia rheumatica – recent Advances and ongoing Questions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Top 10 Compliance risks Facing Physicians PM PS . . . . . . . . . .

Renaissance Washington – Grand ballroom North

Hall D202 b

1.5 hrs

noon – 1:00 pm

arHP networking eventArHP Networking break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Renaissance

Washington – Congressional Hall b

12:45 – 2:15 pm

aCr meet the Professor sessions basic Immunology for Clinical rheumatologists (071) . . . . . . .Fibromyalgia and Dysautonomia (072) . . . . . . . . . . . . . . . . . . .myopathy: Issues in Diagnosis and Treatment (073) . . . . . . . .rheumatoid Arthritis: Challenging Cases (074) . . . . . . . . . . . . .rheumatoid Arthritis: Safety of Novel Therapies (075) . . . . . .Systemic Lupus erythematosus: Central Nervous System (076) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Systemic Lupus erythematosus: Difficult to Treat Systemic Lupus erythematosus (077) . . . . . . . . . . . . . . . . . . . . . . . . . . . .Systemic Lupus erythematosus: Lupus Nephritis (078) . . . . . .Temporal Arteritis (079) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .vasculitis: Update (080) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

148153154 A154 b155 158 A 158 b159 A159 b160

1.5 hrs


23



1:00 – 2:00 pm

aCr sessionsCatastrophic Antiphospholipid Syndrome (Clinical review) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .osteoimmunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Hall Dballroom b

1.0 hrs

1:00 – 2:00 pm

aCr study groups A Primer on educational Theory for medical educators . . . . . .Capillaroscopy in rheumatic Diseases . . . . . . . . . . . . . . . . . . . .Crystal Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Decision Aids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Latin American . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Lupus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .magnetic resonance Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . .Polymyalgia rheumatica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Scleroderma biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Shaping the Future of Psoriatic Disease Care: Current Controversies and Progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sjögren’s Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .veterans Affairs rheumatology . . . . . . . . . . . . . . . . . . . . . . . . .

204 A206207 A146 C140 A202 b201147 A145 A 150 b143 A152 A

1:15 – 3:15 pm

aCr/arHP workshopsClinical Anatomy and Physical exam: essential Tools in Upper extremity regional Pain Syndromes (235) . . . . . . . . . . . . .mrI in the Diagnosis and management of Spondylarthritis: A Clinician’s Guide (236) . . . . . . . . . . . . .Synovial Fluid Analysis and Crystal Identification (237) . . .Web-based Tools for enhancing and managing Teaching and Clinical Practice (238) . . . . . . . . . . . . . . . . . . . . . . . . . . .

144 C 144 b149 A 149 b

2.0 hrs

1:30 – 2:30 pm

aCr sessionACr Leadership Town Hall meeting & business meeting . . . . . ballroom A

2:30 – 4:00 pm

aCr sessionsApproach and management of back Pain in older Adults PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Connective Tissue Disease Associated Interstitial Lung Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .New molecules in Joint biology . . . . . . . . . . . . . . . . . . . . . .visualising the Immuno-inflammatory response . . . . . . . .

Hall e Hall D152 A150 b

1.5 hrs

24




2:30 – 4:00 pm

aCr Concurrent abstract sessionsACr Late-breaking Abstracts Session . . . . . . . . . . . . . . . . . . . . .(#2455-2460) Antiphospholipid Syndrome . . . . . . . . . . . . . . . .(#2461-2466) epidemiology and Health Services research Iv: outcomes and Costs in rheumatic Disease . . . . . . . . . . . . . . . .(#2467-2472) osteoarthritis – Clinical Aspects II: Structural risks for osteoarthritis end-points and Potential Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2473-2478) Pediatric rheumatology: Clinical and Therapeutic Disease III: Childhood Systemic Lupus erythematosus and other vasculidities . . . . . . . . . . . . . . . . . . .(#2479-2484) rheumatoid Arthritis - Clinical Aspects Iv: Non-biologic Drugs for rheumatoid Arthritis: New Insights on Comorbidities and Adverse events . . . . . . . . . . . . . . . . . . . . . . .(#2485-2490) rheumatoid Arthritis Treatment - Small molecules, biologics and Gene Therapy: Safety & efficacy of Janus Activated-Kinase (JAK) Inhibitors . . . . . . . . . . . . . . . . . . .(#2491-2496) Spondyloarthritis and Psoriatic Arthritis - Pathogenesis, etiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2497-2502) Systemic Lupus erythematosus - Human etiology and Pathogenesis II . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2503-2508) T-cell biology and Targets in Autoimmune Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom A147 A 202 b Renaissance Washington – Grand ballroom North

207 A ballroom b ballroom C Salon b 146 C 204 A

1.5 hrs

2:30 – 4:00 pm

aCr/arHP Combined abstract session(#2509-2514) ACr/ArHP Combined epidemiology Abstract Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

201

1.5 hrs

2:30 – 4:00 pm

arHP sessionsmyositis: Pathogenesis, Diagnosis and management . . . . .rheumatic Disease Update: Systemic Lupus Erythematosus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .rheumatoid Arthritis Disease Activity measures and Quality Indicators: Correct Use and Future Directions . . . . . . . . . .Transition Tools for Patients: Pediatric to Adults . . . . . . . .

206 145 A 143 A140 A

1.5 hrs

4:00 – 6:00 pm

aCr workshop Joint Injection Techniques (239) . . . . . . . . . . . . . . . . . . . . . . . . . 144 C

2.0 hrs

4:30 – 5:30 pm

arHP sessionobesity: It is a Chronic Disease . . . . . . . . . . . . . . . . . . . . . . 140 A

1.0 hrs


25



4:30 – 6:00 pm

aCr sessionsDiagnostic Assessments in myopathy . . . . . . . . . . . . . . . . .microrNA and the rheumatic Diseases . . . . . . . . . . . . . . . .Should Ultrasound be Used in rheumatology Practice? . .The Great masqueraders: malignancies in rheumatic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Hall Dballroom bSalon b 146 C

1.5 hrs

4:30 – 6:00 pm

aCr Concurrent abstract sessions(#2515-2520) biology and Pathology of bone and Joint: regulation of bone Cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2521-2526) Innate Immunity and rheumatic Disease . . . . .(#2527-2532) miscellaneous rheumatic and Inflammatory I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2533-2538) osteoarthritis – Clinical Aspects I: Weight, Activity, and metabolic effects on osteoarthritis . . . . . . . . . . .(#2539-2544) rheumatoid Arthritis – Clinical Aspects v: Comorbidities in rheumatoid Arthritis . . . . . . . . . . . . . . . . . . .(#2545-2550) rheumatoid Arthritis Treatment – Small molecules, biologics and Gene Therapy: efficacy of Approved biologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2551-2556) Sjögren’s Syndrome II – Clinical . . . . . . . . . . . . .(#2557-2562) Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment: Psoriatic Arthritis . . . . . . . . . .(#2563-2568) vasculitis: Clinical Aspects . . . . . . . . . . . . . . . . . .

201143 A 145 A 152 A ballroom A Hall e207 A ballroom C202 b

1.5 hrs

4:30 – 6:00 pm

aCr meet the Professor sessions Central Nervous System vasculitis (081) . . . . . . . . . . . . . . . . . .Crystal: Pseudogout (082) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Pulmonary manifestations of rheumatic Disease (084) . . . . . .raynaud’s and Digital Ischemia (085) . . . . . . . . . . . . . . . . . . . . .rheumatoid Arthritis: Safety of Novel Therapies (086) . . . . . .rheumatology Practice 101: Starting out in Practice for the Graduating Fellow (087) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Systemic Lupus erythematosus: Lupus Nephritis (088) . . . . . .Systemic Lupus erythematosus: Novel Treatments (089) . . . . .vaccinations for Patients on biologic Therapies (090) . . . . . . .

148153154 b155158 A 158 b159 A159 b160

1.5 hrs

4:30 – 6:00 pm

Rheumatology Research Foundation special session (#2569-2574) edmond L. Dubois, mD memorial Lectureship: Hydroxychloroquine reduces Thrombosis in Systemic Lupus erythematosus, Particularly in Antiphospholipid Positive Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

147 A

1.5 hrs

26


Meeting At-A-Glance TUESDAY & WEDNESDAY, NOVEMBER 13, 14

4:30: – 6:00 pm

arHP sessionsArthritis and the older Worker . . . . . . . . . . . . . . . . . . . . . .best Practices for ordering Diagnostic Imaging in evaluating rheumatologic Conditions . . . . . . . . . . . . . . . . . . . . . . . . . .The Puzzle of Fatigue in rheumatoid Arthritis: Putting the Pieces Together . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

204 A 150 b 206

1.5 hrs

6:30 – 9:30 pm

industry-supported symposiaSee program book for the list of symposia.

WedNesday, November 14, 2012


7:00 am – 1:00 pm


1.5 hrs

7:30 – 8:30 am

aCr sessionsImmunology of Pregnancy and Impact on Autoimmune Pathogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Neutrophil extracellular Traps (NeTosis) in rheumatic Disease

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .rheumatology roundup: Highlights from the 2012 Annual Scientific meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .The Unintended Consequences of Health Information Technology PM PS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom A 145 A Hall D 143 A

1.0 hrs

7:30 – 8:30 am

arHP sessionsAn Introduction to Immunology . . . . . . . . . . . . . . . . . . . . . .beyond the basics: A real Life example of multiple Imputation for missing Data Problems (research Series) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

201 206

1.0 hrs

9:00 – 10:30 am

aCr sessionsbiosimilars Development: FDA Perspective . . . . . . . . . . . . .IgG4-related Disease – Past Lessons and Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .NIAmS-Sponsored research in rheumatology: 2012 Highlights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .osteoarthritis Therapeutics: Will This be the Decade for breakthroughs? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Predictive biomarkers: A Journey to Personalized Health Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom C Hall D 152 A ballroom b 150 b

1.5 hrs


27

WEDNESDAY, NOVEMBER 14 Meeting At-A-Glance


9:00 – 10:30 am

aCr Concurrent abstract sessions (#2575-2580) b-cell biology and Targets in Autoimmune Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2581-2586) Imaging of rheumatic Diseases III: Computed Tomography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2587-2592) medical education . . . . . . . . . . . . . . . . . . . . . . . .(#2593-2598) Pediatric rheumatology: Clinical and Therapeutic Disease Iv: Childhood Therapeutics and Response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2599-2604) Quality measures and Innovations in Practice management and Care Delivery . . . . . . . . . . . . . . . . . . . . . . . . .(#2605-2610) rheumatoid Arthritis – Clinical Aspects vI: remission and Flare in rheumatoid Arthritis . . . . . . . . . . . . . .(#2611-2616) Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment: Psoriatic Arthritis and Spondyloarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2617-2622) Systemic Lupus erythematosus – Clinical Aspects and Treatment Iv: Therapeutics . . . . . . . . . . . . . . . . . .

147 A 145 A143 A 146 C 207 A ballroom A Salon b Hall e

1.5 hrs

9:00 – 10:30 am

arHP sessionsForming an education and Support Group from the Ground up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .osteoporosis: 2012 Update . . . . . . . . . . . . . . . . . . . . . . . . . .

206201

1.5 hrs

9:00 – 10:30 am

arHP Concurrent abstract sessions (#2623-2628) Systemic Sclerosis, vasculitis, Crohn’s and Spondyloarthropathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2629-2634) Clinical and rehabilitative Aspects of osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

140A 204 A

1.5 hrs

11:00 am – noon

Amyloidosis 2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .mechanisms of Autoinflammatory Diseases . . . . . . . . . . . .

Hall D150 b

1.0 hrs

11:00 am – 12:30 pm

aCr sessionsmaking Sense of Autoantibodies in the Diagnosis of Systemic rheumatic Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .rheumatoid Arthritis – Treating to Target: How to Incorporate rheumatoid Arthritis Disease Activity measures into routine Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ballroom C Hall e

1.5 hrs

28



11:00 am – 12:30 pm

aCr Concurrent abstract sessions (#2635-2640) epidemiology and Health Services research v: rheumatoid Arthritis management in the Treat-to-Target era . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2641-2646) Fibromyalgia and Soft Tissue Disorders II . . . . . .(#2647-2652) orthopedics, Low back Pain, and rehabilitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2653-2658) Pediatric rheumatology – Pathogenesis and Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2659-2664) rheumatoid Arthritis – Clinical Aspects vII: Prediction of outcome in rheumatoid Arthritis . . . . . . . . . . . .(#2665-2670) rheumatoid Arthritis – Human etiology and Pathogenesis II: Cellular effectors of rheumatoid Arthritis and Novel rheumatoid Arthritis Genome-Wide Association Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2671-2676) Sjögren’s Syndrome I – Pathogenesis . . . . . . . . .(#2677-2682) Systemic Lupus erythematosus – Animal models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2683-2688) Systemic Lupus erythematosus – Clinical Aspects and Treatment v: Clinical Aspects . . . . . . . . . . . . . . . .

207 A202 b 145 A 143 A ballroom A 146 C147 A 152 A ballroom b

1.5 hrs

11:00 am – 12:30 pm

arHP sessionsHighlights from the 2012 ArHP Sessions . . . . . . . . . . . . . . .Shoulder Pain and rotator Cuff Tear in rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

201 206

1.5 hrs

11:00 am – 12:30 pm

arHP Concurrent abstract sessions (#2689-2694) Factors Associated with rheumatoid Arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .(#2695-2700) Systemic Lupus erythematosus . . . . . . . . . . . . . .

140 A204 A

1.5 hrs

1:00 – 4:00 pm

industry-supported Post Conference symposiaSee program book for the list of symposia.

Meeting At-A-Glance WEDNESDAY, NOVEMBER 14


29

Innovation Theater

These non-Cme accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhrmA Code on Interactions with Healthcare Professionals.

all innovation theater presentations will be held in Hall a (Booth #1451) at their designated time.

sunday, novemBer 11, 2012

10:30 - 11:15 am

aCtemra monotherapy: from Clinical trial experience to Clinical PracticePresented by Genentech, a member of the Roche Group

2:30 - 3:15 pm

role of multi-Biomarker test in ra Patient managementPresented by Crescendo Bioscience

monday, novemBer 12, 2012

10:30 - 11:15 am

rituxan ra - Pivotal and long-term efficacy and safety dataPresented by Genentech, a member of the Roche Group

12:30 - 1:15 pm

introducing an innovative new Patient educational and support Program Presented by Janssen Biotech, Inc.

2:30 - 3:15 pm

Case studies: Practical management of goutPresented by Takeda Pharmaceuticals

tuesday, novemBer 13, 2012

10:30 - 11:15 am

evaluation of Clinical endpoints for sle disease activity in worldwide Clinical trials: optimization of treatment effects through targeted training and Centralized data reviewPresented by ReSearch Pharmaceutical Services, Inc.

12:30 - 1:15 pm

are you using your father’s Prednisone to treat your mother’s ra?: new understanding of a familiar therapyPresented by Horizon Pharma

2:30 - 3:15 pm

Pathophysiology of Pain: Processes, Plasticity, and PerceptionPresented by Lilly USA, LLC

30


MAP conference center

Lower LevelHalls A, B & C

1

2

1 Exhibit HallCareer ConnectionFirst AidGraffiti WallInnovation TheaterRecharge StationsWi-Fi Way

2 Poster HallPoster Service CenterPoster Tours


31

conference center MAP

ConcourseHalls A, B & C

1 CME/Internet Center

1

32



Street LevelGrand Lobby/Registration/Salons A–I

Meeting Rooms 101–103 & 140–160

RETAIL

1 ACR OfficeLost and Found

2 Business CenterIndustry-Supported Symposia Information

3 Metro Station4 Nursing Mothers’ Room5 Prayer Room6 Registration

Coat/Baggage Check Hotel ReservationsMembership BoothRheumatology Research Foundation 5K Run/Walk RegistrationRibbon Distribution

7 Speaker Lounge8 Speaker Ready Room9 Visitor Information

Graffiti WallRestaurant ReservationsWheelchairs (complimentary-limited availability)

38 7

62 9

4 5

1


33


Level TwoHalls D & EMeeting Rooms 201-210East and West Overlook

GRAND LOBBY BRIDGE

1 Newsroom2 Opening Lecture and Awards3 Resource Center

Rheumatology Research Foundation Booth

4 Rheumatology Research Foundation Donor’s Lounge

5 SessionSelect Lounge

5

4

1

3

2

34



1

2

Level ThreeBallrooms

1 Attendee LoungeRecharge Stations

2 Late-breaking Abstract PresentationsTown Hall and Business Meeting


35


Exhibit HallHall B

1 CME/Internet Center

1


See following spread for Exhibitor legend

36



Exhibit HallList of Exhibitors

1254 4S Dawn Clinical Software

1005 Abbott

214 ACP/Annals of Internal Medicine

924 ACR Simple Tasks

1045 Actelion Pharmaceuticals

420 Aesku Inc

1049 American Regent, Inc.

900 Amgen, Inc.

707 Amgen, Inc. and Pfizer Inc.

304 Arthritis Foundation

413 Arthritis Health Monitor TV

311 Autoimmune Diseases Association

553, 658

Auxilium Pharmaceuticals

658 Auxilium Pharmaceuticals

512 Besse Medical

438 BioMed Central

422 Bioventus LLC

1252 Bristol-Myers Squibb

206British Society for Rheumatology

1513 Buzzy4Shots.com

1519 Cardinal Health

819 Celgene Corporation

843 Cellestis, a QIAGEN Company

361 Celltrion Healthcare Co., Ltd.

761 Chugai Pharmaceutical Co., Ltd.

221 Cleveland Clinic

559 Clinical and Experimental Rheumatology

1421 ContextMedia: Health’s Rheumatoid Health Network

748 Corinthian Reference Lab

1509 CORRONA, Inc.

1247 Crescendo Bioscience, Inc.

1419 CuraScript SD

639 CVS/Caremark Speciality Pharmacy

1153 DePuy Mitek

1614 DynaMed/EBSCO Publishing

357 eClinicalworks

902 Elsevier, Inc.

1343 Esaote North America

506 Euroimmun US

315 European League Against Rheumatism (EULAR)

1142 Exhibitchek

514 Ferring Pharmaceuticals Inc.

641 Fidia Pharma USA

747 Forest Pharmaceuticals, Inc.

741 GE Healthcare

507 Genentech and Roche

1146 Genzyme, a Sanofi Company

537 Gilead Sciences, Inc.

1522 GlaxoSmithKline

205 Gout & Uric Acid Education Society (GUAES)

738 Hattiesburg Clinic

1518 HealthWell Foundation

940 Hologic

545 Horizon Pharma, Inc.

744 Hospira

319 Hospital for Special Surgery

406 HRA Healthcare Research & Analytics

1308 Human Genome Sciences, Inc.

746 Immco Diagnostics, Inc.

956 Inova Diagnostics, Inc.

1536 Intellogics

339 JAMA Network

1023, 1226 Janssen Biotech

801 Johns Hopkins Arthritis Center

318 Journal of Rheumatology, The

857 LabCorp

601 La Lettre Du Rhumatologue - Edimark Santé

212 Letter to Editor Rheumatology

1327 Lilly USA, LLC.

853 Lippincott, Williams and Wilkins

452 Lone Oak Medical Technology

1043 Lupus Initiative, The

BOOTH | EXHIBITOR

Exhibit HallList of Exhibitors


37

740 Mayo Clinic

1515 McKesson Specialty Health

847 medac pharma, Inc.

327 MedImmune, LLC

1537 Merck

308 METEOR

849 Metro Medical Supply

418 Metroplex Clinical Research Center

310 Myositis Association, The

215 National Data Bank for Rheumatic Diseases

305 National Fibromyalgia Partnership, Inc.

213National Institute of Arthritis and Musculoskeletal and Skin Diseases

209 National Scleroderma Core Centers

208Northwestern University Division of Rheumatology

1218Novartis Pharmaceuticals Corporation

618 Nutramax Laboratories, Inc.

321NYU Langone Medical Center – NYU Hospital for Joint Diseases

207 OMERACT

1305 Optasia Medical, Inc

211 Organization of Teratology Information Specialists

637 Ossur Americas

952 Oxford Immunotec Inc

404 Oxford University Press

313 PANLAR

1404 PatientPoint®

423 Pfizer, Inc.

724 Pfizer, Inc.

210 Pulmonary Hypertension Association

1443 Questcor Pharmaceuticals, Inc.

407 Quidel Corporation

219 R. J. Fasenmyer Center for Clinical Immunology

619 RDL Reference Laboratory

1147 Regeneron Pharmaceuticals, Inc.

1144 ReSearch Pharmaceutical Services

510Rheumatoid Patient Foundation

1439 Rheumatology News

309 Rheumatology Nurses Society

1437 Rheumatology Practice News

825 Rottapharm Ltd

645 Sanofi Biosurgery

343 Savient Pharmaceuticals

320 Scandinavian Journal of Rheumatology

303 Scleroderma Foundation

412 Scott & White Healthcare

355 SI-BONE

946 Siemens Medical Solutions USA Inc.

736 Silver Ring Splint Company

204 Sjogrens Syndrome Foundation

944 SNBL

1253 SOBI

501 SonoSite

314 Spondylitis Association of America

436 Springer

1261 Takeda Pharmaceuticals

410

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis

337 TheraTest Laboratories, Inc.

845 Trimer Biotech, LLC

414 TSI Healthcare

1137 UCB, Inc.

415United Regional Health Care System

519 UpToDate

307 US Pain Foundation Inc

649 Value-Based Care in Rheumatology

312 Vasculitis Foundation

353 Vindico Medical Education

653 VQ OrthoCare

841 Wiley Blackwell

456 Zimmer

BOOTH | EXHIBITOR


My Annual Meeting – Everything you need, all in one place.

Log-in to My Annual Meeting using your ACR/ARHP username and password to…

• Create your itinerary

• View syllabi

• Track your CME

• Acquire your CME certificate

• Provide session feedback

• Open SessionSelect

Practicing rheumatology isn’t easy. Navigating the ACR/ARHP Annual Meeting is!

Browse the program and search abstracts online with ease!

Check out these and other annual meeting resources at www.ACRannualmeeting.org!

ENEB

RO12

0 Se

ssio

n Tr

acke

r JA

TRIM

: 6"

x 9"

BLEE

D: .1

25"

LIVE

: 5"

x 8"

vv

7/1

8/12

Enbrel® (etanercept) Brief SummarySEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

WARNINGSSERIOUS INFECTIONS AND MALIGNANCIESPatients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.Enbrel should be discontinued if a patient develops a serious infection or sepsis.Reported infections include:• Active tuberculosis, including reactivation of latent tuberculosis.

Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use.

• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.

• Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.MALIGNANCIESLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel.

INDICATIONS AND USAGERheumatoid ArthritisEnbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone.Polyarticular Juvenile Idiopathic ArthritisEnbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older.Psoriatic ArthritisEnbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone.Ankylosing SpondylitisEnbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS).Plaque PsoriasisEnbrel is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.CONTRAINDICATIONSEnbrel should not be administered to patients with sepsis.WARNINGS AND PRECAUTIONSSerious InfectionsPatients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease.Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients: with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection, such as advanced or poorly controlled diabetes [see Adverse Reactions].Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel.Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated.TuberculosisCases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel.Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with

tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG).

Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating anti-tuberculosis therapy is appropriate for an individual patient.Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.Invasive Fungal InfectionsCases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of antifungal therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel.Neurologic EventsTreatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions].MalignanciesLymphomasIn the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months).Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general US population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity.Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials.LeukemiaCases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia.During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months).Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years.Other MalignanciesInformation is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies.For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general US population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown.Melanoma and Non-melanoma skin cancer (NMSC)Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept. Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient- years of therapy, the observed rate of melanoma was 0.043 cases per 100 patient-years.Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult psoriasis patients treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years. Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel.

Periodic skin examinations should be considered for all patients at increased risk for skin cancer.Pediatric PatientsMalignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at ≤ 18 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.In clinical trials of 696 patients representing 1282 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported.Postmarketing UseIn global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported.Patients With Heart FailureTwo clinical trials evaluating the use of Enbrel in the treatment of heart failure were terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully.

Hematologic EventsRare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities.Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 109/L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy.Hepatitis B Virus ReactivationUse of TNF-blocking agents has been associated with reactivation of hepatitis B virus (HBV), including very rare cases (< 0.01%) with Enbrel, in patients who are chronic carriers of this virus. In some instances, HBV reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to HBV reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers for patients identified as carriers of HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients who are carriers of HBV and require treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation.

Allergic ReactionsAllergic reactions associated with administration of Enbrel during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated.

Caution: The needle cap on the prefilled syringe and on the SureClick autoinjector contains dry natural rubber (a derivative of latex) that may cause allergic reactions in individuals sensitive to latex.

ImmunizationsLive vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions].

AutoimmunityTreatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated.

ImmunosuppressionTNF mediates inflammation and modulates cellular immune responses. TNF-blocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Adverse Reactions].

Use in Wegener’s Granulomatosis PatientsThe use of Enbrel in patients with Wegener’s granulomatosis receiving immunosuppressive agents is not recommended. In a study of patients with Wegener’s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions].

Use with Anakinra or AbataceptUse of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions].

B:9.25 inB:6.25 in

T:9 inT:6 in

S:8 inS:5 in

ENEB

RO12

0 Se

ssio

n Tr

acke

r JA

TRIM

: 6"

x 9"

BLEE

D: .1

25"

LIVE

: 5"

x 8"

vv

7/1

8/12

Use in Patients with Moderate to Severe Alcoholic HepatitisIn a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis.

ADVERSE REACTIONSAcross clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions.

Clinical Studies ExperienceAdverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis

The data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months.

In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied.

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice.

InfectionsInfections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents.

In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in RA and PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza.

In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in PsO, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials.

In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the US and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions].

Injection Site ReactionsIn placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of patients treated with Enbrel developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given.

ImmunogenicityPatients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel.In PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6%–8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown.The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to etanercept with the incidence of antibodies to other products may be misleading.

AutoantibodiesPatients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions].

Other Adverse ReactionsTable 3 summarizes adverse reactions reported in adult RA patients.

The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA.

Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials

Placebo Controlleda

(Studies I, II, and a Phase 2 Study)

Active Controlledb

(Study III)

Placebo (N = 152)

Enbrelc

(N = 349)MTX

(N = 217)Enbrelc

(N = 415)

Reaction Percent of Patients Percent of Patients

Infectiond (total)Upper Respiratory Infectionse

Non-upper Respiratory InfectionsInjection Site ReactionsDiarrheaRashPruritusPyrexiaUrticariaHypersensitivity

3930

15

11

921–1–

5038

21

37

8323––

8670

59

18

16195441

8165

54

43

16135221

a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms.

bStudy duration of 2 years.cAny dose.dIncludes bacterial, viral, and fungal infections.e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis, and influenza.

In placebo-controlled PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group.Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II.

Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials

(Studies I & II)

Placebo(N = 359)

Enbrela

(N = 876)

Reaction Percent of Patients

Infectionb (total)Non-upper Respiratory InfectionsUpper Respiratory Infectionsc

Injection Site ReactionsDiarrheaRashPruritusUrticariaHypersensitivityPyrexia

2814

17

6

212––1

2712

17

15

31111–

a Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses.

bIncludes bacterial, viral and fungal infections.c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis.

Adverse Reactions in Pediatric PatientsIn general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions]. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae.In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children.Postmarketing ExperienceAdverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure.

Adverse reactions are listed by body system below:

Blood and lymphatic pancytopenia, anemia, leukopenia,system disorders: neutropenia, thrombocytopenia, lymphadenopathy, aplastic anemia [see Warnings and Precautions]Cardiac disorders: congestive heart failure

[see Warnings and Precautions]Gastrointestinal disorders: inflammatory bowel disease (IBD)General disorders: angioedema, chest painHepatobiliary disorders: autoimmune hepatitis, elevated

transaminasesImmune disorders: macrophage activation syndrome, systemic vasculitisMusculoskeletal and lupus-like syndromeconnective tissue disorders:Neoplasms benign, melanoma and non-melanomamalignant, and unspecified: skin cancers, merkel cell carcinoma [see Warnings and Precautions]Nervous system disorders: convulsions, multiple sclerosis,

demyelination, optic neuritis, transverse myelitis, paresthesias [see Warnings and Precautions]

Ocular disorders: uveitis, scleritisRespiratory, thoracic interstitial lung diseaseand mediastinal disorders:Skin and subcutaneous cutaneous lupus erythematous, tissue disorders: cutaneous vasculitis (including leukocytoclastic vasculitis), erythema multiforme, Stevens-Johnson syndrome, toxic

epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar)Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use.

DRUG INTERACTIONSSpecific drug interaction studies have not been conducted with Enbrel.

VaccinesMost PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel.

Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions].

Immune-Modulating Biologic ProductsIn a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 109/L).

In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions].

CyclophosphamideThe use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions].

SulfasalazinePatients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown.

USE IN SPECIFIC POPULATIONSPregnancyPregnancy Category B. Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 100-fold higher than the human dose and have revealed no evidence of harm to the fetus due to Enbrel. There are, however, no studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Pregnancy Registry: To monitor outcomes of pregnant women exposed to Enbrel, a pregnancy registry has been established. Physicians are encouraged to register patients by calling 1-877-311-8972.

Nursing MothersIt is not known whether Enbrel is excreted in human milk or absorbed systemically after ingestion. Because many drugs and immunoglobulins are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Enbrel, a decision should be made whether to discontinue nursing or to discontinue the drug.

Pediatric UseEnbrel is indicated for treatment of polyarticular JIA in patients ages 2 years and older [see Indications and Usage, Warnings and Precautions, Adverse Reactions].

Enbrel has not been studied in children < 2 years of age with JIA. The safety and efficacy of Enbrel in pediatric patients with PsO have not been studied.

Rare (<0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is not effective for the treatment of IBD [see Adverse Reactions].

Geriatric UseA total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965 subjects treated with Enbrel or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO subjects is too small to determine whether they respond differently from younger subjects. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly.

Use in DiabeticsThere have been reports of hypoglycemia following initiation of Enbrel therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.Rx Only.

This brief summary is based on ENBREL prescribing information v. 48: 12/2011

Manufactured by: Immunex Corporation

Thousand Oaks, CA 91320-1799US License Number 1132

Marketed by Amgen Inc. and Pfizer Inc.

© 1998 – 2011 Immunex Corporation. All rights reserved.

US Patent Nos. 7,915,225; 5,605,690; Re. 36,755.

For more information please call 1-888-436-2735 or visit www.enbrel.com

©2010 Amgen Inc., Thousand Oaks, CA 91320 and Pfizer Inc. All rights reserved.©2011 Amgen Inc., Thousand Oaks, CA 91320 and Pfizer Inc. All rights reserved.

B:9.25 inB:6.25 in

T:9 inT:6 in

S:8 inS:5 in

ENEB

RO12

0 Se

ssio

n Tr

acke

r JA

TRIM

: 6"

x 9"

BLEE

D: .1

25"

LIVE

: 5"

x 8"

vv

7/1

8/12

© 2012 Amgen Inc., Thousand Oaks, CA 91320 and Pfizer Inc. All rights reserved. 61043-R4-V4 07-12

www.enbrel.com/rheumpro

References: 1. Data on file, Pfizer Inc. 2. Klareskog L, van der Heijde D, de Jager JP, et al; for the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-681.

Prescription Enbrel® (etanercept) is administered by injection.

IMPORTANT SAFETY INFORMATION

SERIOUS INFECTIONSPatients treated with ENBREL are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosup-pressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumo-cystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.

MALIGNANCIESLymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL.

In adult clinical trials of all TNF blockers, more cases of lym-phoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown.

Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.

Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.

Pediatric PatientsIn patients who initiated therapy at ≤18 years of age, ap-proximately half of the reported malignancies were lym-phomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.

NEUROLOGIC EVENTSTreatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with

peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexist-ing or recent-onset central or peripheral nervous system demyelinating disorders. CONGESTIVE HEART FAILURECases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored.

HEMATOLOGIC EVENTS Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed.

HEPATITIS B VIRUS REACTIVATIONUse of TNF blockers, including ENBREL, has been associ-ated with reactivation of hepatitis B virus (HBV) in chronic carriers of this virus. The majority of these reports occurred in patients on concomitant immunosuppressive agents, which may also contribute to HBV reactivation. Exercise caution when considering ENBREL in patients identified as carriers of HBV.

ALLERGIC REACTIONSAllergic reactions have been reported in <2% of patients in clinical trials of ENBREL.

IMMUNIZATIONSLive vaccines should not be administered to patients on ENBREL. JIA patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, consider temporary discontinuation of ENBREL and prophylactic treatment with Varicella Zoster Immune Globulin.

AUTOIMMUNITYAutoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops.

WEGENER’S GRANULOMATOSIS PATIENTSThe use of ENBREL in patients with Wegener’s granulomatosis receiving immunosuppressive agents (e.g., cyclophosphamide) is not recommended.

MODERATE TO SEVERE ALCOHOLIC HEPATITISBased on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis.

ADVERSE EVENTSThe most commonly reported adverse events in RA clinical trials were injection site reaction, infection, and headache. In clinical trials of all other adult indications, adverse events were similar to those reported in RA clinical trials.

DRUG INTERACTIONSThe use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in antidiabetic medication in some of these patients.

Please see adjacent Brief Summary of Prescribing Information.

B:9.25 inB:6.25 in

T:9 inT:6 in

S:8 inS:5 in

ENEB

RO12

0 Se

ssio

n Tr

acke

r JA

TRIM

: 6"

x 9"

BLEE

D: .1

25"

LIVE

: 5"

x 8"

vv

7/1

8/12

When you have decided a biologic is the next step

Choose ENBREL

for appropriate moderate to severe RA patients

IndicationENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active RA. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

Important Safety InformationENBREL has been shown to increase the risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens, and should be discontinued if a patient develops a serious infection or sepsis. Test for latent TB (if positive, start treatment for TB prior to starting ENBREL) and monitor for active TB during treatment. Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with tumor necrosis factor (TNF) blockers, including ENBREL.

Please see additional Important Safety Information and Brief Summary of Prescribing Information on the adjacent pages.

TEMPO was a 3-year, multicenter, double-blind, clinical trial of 682 patients with moderately to severely active RA (mean disease duration: 7 years), who had an inadequate response to at least 1 DMARD excluding MTX. At baseline: patients were ≥18 years of age, MTX-naïve, had an ESR ≥28 mm/hr or CRP ≥20 mg/L, and were in ACR functional class I, II, or III.1,2

Call ENBREL Support™ after you prescribe: 1-888-4ENBREL

www.enbrel.com/rheumpro

ENBREL provided rapid and sustained efficacy in patients with moderate to severe RAACR 20 Responses at Week 2, Year 1, and Year 3 (NRI) were1:

44%, 75%, and 52% for ENBREL + MTX* 19%, 59%, and 33% for MTX only

*P<0.001 vs MTX at all timepointsNRI=Nonresponder imputation

Visit us at booth 707

B:9.25 inB:6.25 in

T:9 inT:6 in

S:8 inS:5 in

Documents

2012 ACR/ARHP ANNUAL MEETING session...306 – Systemic Lupus erythematosus: Clinical Aspects 10:15 – 11:00 am 307 – osteoarthritis - Clinical Aspects 308 – rheumatoid Arthritis